Damora Therapeutics, Inc. (DMRA)
NASDAQ · Healthcare
$32.99+4.80%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $1.86B
- P/E ratio
- —
- EPS
- —
- Volume
- 350,425
- 52-week high
- —
- 52-week low
- —
- Open
- $31.48
- Day high
- $34.89
- Day low
- $31.48
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$209.84M | $3.98 |
| 2024 | — | -$21.44M | -$18.53 |
| 2023 | — | -$38.35M | -$36.08 |
| 2022 | — | -$61.62M | -$2.43 |
| 2021 | — | -$51.75M | -$2.05 |
About Damora Therapeutics, Inc.
Galecto, Inc. is a clinical-stage biotechnology company dedicated to pioneering innovative small molecule therapeutics. These treatments are specifically engineered to address core biological pathways implicated in both cancer and fibrotic disorders. The firm is also actively developing small molecule inhibitors targeting galectin-3 and LOXL2. Established in 2011 by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye, its corporate operations are based in Boston, Massachusetts.
- CEO
- Jennifer A. Jarrett
- Employees
- 7
- Country
- US
- IPO date
- Mar 10, 2026
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Damora Therapeutics, Inc.'s stock price today?
- DMRA is trading at $32.99 as of Jul 20, 2026.
- What is Damora Therapeutics, Inc.'s market cap?
- Damora Therapeutics, Inc. (DMRA) has a market capitalization of $1.86B.
- Does Damora Therapeutics, Inc. pay a dividend?
- Damora Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Damora Therapeutics, Inc. in?
- Damora Therapeutics, Inc. operates in the Healthcare sector.